GlaxoSmithKline’s two-drug HIV bet just paid off.
Novo Nordisk is about to take on a task that’s so far foiled its peers: expanding the global obesity market.
Two of Roche's newest drugs—including the just-approved hemophilia therapy Hemlibra—racked up data that bolster their case for $1 billion-plus sales.
Atopic dermatitis awareness is again at the center of a Sanofi and Regeneron skin health campaign.
GSK just inherited its biggest threat to Nucala in the form of a new AZ rival. But the British drugmaker says it’s down for some marketplace battling.
A bigger portion of Regeneron's Eylea revenue might be in jeopardy than some analysts had predicted. But a new nod could save the day.
Calling all digital entrepreneurs: Johnson & Johnson is looking for creative tech skincare solutions in its Digital Beauty QuickFire Challenge.
Pfizer’s old dog Sutent has shown it has one more trick to perform as a renal cancer treatment before being passed up by the new breed of I-O drugs.
Astellas has joined the biopharma who's who of companies to disclose federal scrutiny for donations to charities that help patients cover drug costs.
Eli Lilly faces allegations it ran a "multi-tiered kickback scheme" to pump up sales of key diabetes drugs.